Domains of apoE4 required for the biogenesis of apoE-containing HDL

References

• Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, . Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343–53.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, . Familial apolipoprotein E deficiency. J Clin Invest. 1986;78:1206–19.
   PubMed Web of Science ®Google Scholar
• Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141–7.
   PubMed Web of Science ®Google Scholar
• Herz J, Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol. 1995;6:97–103.
   PubMedGoogle Scholar
• Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, . Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem. 1996; 271:8373–80.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992;89:9252–6.
   PubMed Web of Science ®Google Scholar
• Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J. 2007;403:359–67.
   PubMedGoogle Scholar
• Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, . Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med. 2008;40 Suppl 1:14–28.
   PubMedGoogle Scholar
• Hughes SD, Verstuyft J, Rubin EM. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17: 1725–9.
   PubMedGoogle Scholar
• Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39:313–21.
   PubMedGoogle Scholar
• Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet. 1981;33:11–24.
   PubMed Web of Science ®Google Scholar
• Zannis VI, Zanni EE, Makrides SC, Kardassis D, Aleshkov S. Role of apolipoprotein E in Alzheimer's disease. In: Catravas JD. NATO ASI Series, Life Sciences. New York: Plenum Press; 1998. p. 179–209.
   Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–3.
   PubMed Web of Science ®Google Scholar
• Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501–13.
   PubMed Web of Science ®Google Scholar
• Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005;280: 43224–35.
   PubMedGoogle Scholar
• Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, . Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236–42.
   PubMed Web of Science ®Google Scholar
• Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, . Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671–82.
   PubMed Web of Science ®Google Scholar
• Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, von Eckardstein A, . The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem. 2003;278:6719–30.
   PubMedGoogle Scholar
• Liu T, Krieger M, Kan HY, Zannis VI. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem. 2002;277:21576–84.
   PubMedGoogle Scholar
• Kypreos KE, Van Dijk KW, van Der Zee A, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl- terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem. 2001;276: 19778–86.
   PubMedGoogle Scholar
• He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95:2509–14.
   PubMed Web of Science ®Google Scholar
• Chroni A, Kan HY, Shkodrani A, Liu T, Zannis VI. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry. 2005;44: 4108–17.
   PubMedGoogle Scholar
• Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry. 2005;44:13132–43.
   PubMedGoogle Scholar
• Chroni A, Duka A, Kan HY, Liu T, Zannis VI. Point mutations in apolipoprotein a-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 2005;44:14353–66.
   PubMedGoogle Scholar
• Li X, Kypreos K, Zanni EE, Zannis V. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: Implications for the functions of apoE in the brain. Biochemistry. 2003;42:10406–17.
   PubMedGoogle Scholar
• Fielding CJ, Fielding PE. Two-dimensional nondenaturing electrophoresis of lipoproteins: applications to high-density lipoprotein speciation. Methods Enzymol. 1996;263:251–9.
   PubMed Web of Science ®Google Scholar
• Chroni A, Kan HY, Kypreos KE, Gorshkova IN, Shkodrani A, Zannis VI. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry. 2004;43:10442–57.
   PubMedGoogle Scholar
• Hill JS, O K, Wang X, Paranjape S, Dimitrijevich D, Lacko AG, . Expression and characterization of recombinant human lecithin:cholesterol acyltransferase. J Lipid Res. 1993;34:1245–51.
   PubMed Web of Science ®Google Scholar
• Jin L, Lee YP, Jonas A. Biochemical and biophysical characterization of human recombinant lecithin: cholesterol acyltransferase. J Lipid Res. 1997;38:1085–93.
   PubMedGoogle Scholar
• Amar MJA, Shamburek RD, Foger B, Hoyt RF, Wood DO, Santamarina-Fojo S, . Adenovirus-mediated expression of LCAT in non-human primates leads to an antiatherogenic lipoprotein profile with increased HDL and decreased LDL. Circulation. 1998;98:35.
   Google Scholar
• Laccotripe M, Makrides SC, Jonas A, Zannis VI. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J Biol Chem. 1997;272:17511–22.
   PubMed Web of Science ®Google Scholar
• Matz CE, Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982;257: 4535–40.
   PubMed Web of Science ®Google Scholar
• Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. Reconstituted discoidal apoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of apoE suffices for receptor binding. J Biol Chem. 2002;277: 21149–57.
   PubMedGoogle Scholar
• Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:276–94.
   PubMed Web of Science ®Google Scholar
• Chroni A, Koukos G, Duka A, Zannis VI. The carboxy- terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 2007;46:5697–708.
   PubMedGoogle Scholar
• Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988;263:6249–58.
   PubMedGoogle Scholar
• Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988;263: 6240–8.
   PubMedGoogle Scholar
• Gorshkova IN, Liu T, Kan HY, Chroni A, Zannis VI, Atkinson D. Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry. 2006;45:1242–54.
   PubMedGoogle Scholar
• Nolte RT, Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J. 1992;63:1221–39.
   PubMedGoogle Scholar
• Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor- binding domain of human apolipoprotein E. Science. 1991;252:1817–22.
   PubMedGoogle Scholar
• Steinmetz A, Kaffarnik H, Utermann G. Activation of phosphatidylcholine-sterol acyltransferase by human apolipoprotein E isoforms. Eur J Biochem. 1985;152:747–51.
   PubMedGoogle Scholar
• Chen CH, Albers JJ. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. Biochim Biophys Acta. 1985;836: 279–85.
   PubMed Web of Science ®Google Scholar
• Kypreos KE, Zannis VI. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res. 2006;47:521–9.
   PubMedGoogle Scholar
• Kypreos KE, Van Dijk KW, Havekes LM, Zannis VI. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. J Biol Chem. 2005;280:6276–84.
   PubMedGoogle Scholar
• Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg) FIN. Biochemistry. 2007;46:10713–21.
   PubMedGoogle Scholar